Circulating-tumor DNA Assessment in Diffuse Large B-cell Lymphoma to Determine Up-front Stem Cell Transplantation: A Pilot Study

Juhyung Kim, Tan Minh Le, Donghyeon Lee, Hong Duc Thi Nguyen, Hee Jeong Cho, Sang Kyun Sohn, Jong Gwang Kim, Shin Young Jeong, Ji Yeon Ham, Ji Yun Jeong, Hyung Soo Han, Joon Ho Moon, Dong Won Baek

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Background/Aim: This study evaluated the possibility of clinical use of circulating-tumor DNA (ctDNA) as a biomarker to determine up-front autologous stem cell transplantation (auto-SCT) for patients with high-risk diffuse large B-cell lymphoma (DLBCL) in practice. Patients and Methods: To explore the dynamics of ctDNA in DLBCL, blood samples were collected sequentially before and after treatment from patients with newly diagnosed DLBCL who received rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. To conduct ctDNA genotyping and ctDNA monitoring simultaneously, targeted sequencing by cancer personalized profiling using deep sequencing was used. Results: Ten patients between the ages of 50 and 60 years were enrolled. Based on the international prognostic index (IPI), seven patients were classified as high-IPI-risk group, and three patients were classified as low-IPI-risk group. The IPI risk group correlated with total metabolic tumor volume. All patients completed six cycles of R-CHOP chemotherapy, and seven patients achieved complete response. Changes in ctDNA mutation numbers did not correlate with changes in PET scan images and treatment response. In most high-risk patients, new mutations appeared in ctDNA after completion of chemotherapy that conceivably marked resistant clones. Notably, disease relapse did not occur in high-risk patients with poor prognostic mutations who underwent autologous SCT. Conclusion: ctDNA monitoring was meaningful in high-risk patients. Moreover, ctDNA and well-known prognostic factors should be considered in the decision making for auto-SCT. If a new genetic mutation in ctDNA with a negative prognosis would emerge during treatment, high-risk patients should consider auto-SCT.

Original languageEnglish
Pages (from-to)372-379
Number of pages8
JournalIn Vivo
Volume38
Issue number1
DOIs
StatePublished - Jan 2024

Keywords

  • Circulating-tumor DNA
  • diffuse large B-cell lymphoma
  • stem cell transplantation
  • survival

Fingerprint

Dive into the research topics of 'Circulating-tumor DNA Assessment in Diffuse Large B-cell Lymphoma to Determine Up-front Stem Cell Transplantation: A Pilot Study'. Together they form a unique fingerprint.

Cite this